PDO Screen: a patient in the lab

drug screening platform

Advance your lead agent with confidence using patient-derived organoids

PDO Screen is our newly designed drug screening platform that allows you to maximize your chance of success in the clinic. Choose from an extensive collection of well-characterized patient-derived organoid (PDO) models as patient avatars for your drug screening program and prioritize your clinical candidate with confidence.

We have carefully selected a panel of more than 100 patient-derived organoids (PDOs) from multiple different disease indications including cancer, FAP IBD, and COPD across 9 different tissue types.

Screen features:

Select any number of PDO models across 9 different tissue types
Test your compound/s in triplicates
ATP-based cell viability 3D assay with IC₅₀ readouts
10-point dose-response curve/drug
Staurosporin/DMSO controls included
Additional readouts available include morphology evaluation (brightfield, IF), IHC, western blot, and RT-PCR
Barrier function and cytokine production assays for IBD and COPD

Our standard screening is specifically designed to evaluate your compound efficacy and cytotoxicity and offers reliable pharmacology data faster compared to translational in vivo models. A customized design will be set up for COPD and IBD studies.

Project delivery timeline from 8 weeks depending on model selection and number of compounds.

Why choose PDO Screen

Clinical relevance: our world-leading technology for organoid development ensure key patient and disease features are indefinitely preserved in 3D culture
Quality assurance: SNP-verified, annotated models with DNA, and RNA sequencing data available
Target driven drug development: with hotspot mutational analysis performed on a selection of models available for PDO Screen
Faster and more cost-effective than ever: our optimised drug screening workflow provides results in weeks